Based on our overall results where DBeQ demonstrates better efficacy in the functional assays as compared to NMS-873, we selected DBeQ for encapsulation into the dendrimer to improve its effectiveness in selectively targeting tumor cells and allowing controlled drug release for selective VCP mediated proteostasis-inhibition of NSCLC. Here, VCP is linked to non-small cell lung carcinoma.